Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us
Pipeline Breakdown

Which pathogens are receiving most attention in R&D?

The World Health Organization and US Centers for Disease Control have identified the most dangerous pathogens due to resistance. The Benchmark has examined which of the eight large research-based companies in scope are working on treatments and vaccines that target them.

Date

18 November 2021

  • Six of the eight companies in scope are targeting pathogens in the highest threat categories use by WHO and the US CDC, including 18 projects in clinical-stage development or recently approved

  • Six of the companies evaluated are developing vaccines (30) for the pathogens in scope.

The 2021 Antimicrobial Resistance Benchmark examines the antibacterial and antifungal pipelines of eight large research-based pharmaceutical companies. By volume and value of sales, these are the largest players in the global market for antibacterial medicines that are active in innovative R&D today. The aim is to capture how these companies are supporting global efforts to replenish and protect the antimicrobial pipeline.

The Benchmark focuses on R&D projects that target the priority bacteria and fungi identified by WHO2 and the CDC as being of particular concern due to drug resistance, for which there is an urgent global need for new treatments. Collectively, the eight companies evaluated have 92 R&D projects in the R&D pipeline that target these 'priority pathogens'. 

Where research is currently targeted:

Are projects targeting the most critical and urgent pathogens?

There are three levels of prioritisation in the WHO priority list: critical, high, and medium, and four levels of threat in the CDC list: urgent, serious, concerning and watch. Six of the pathogens fall into one or other of these prioritisation categories, including Candida auris, one of only two fungal pathogens on either list. Many strains of C.auris are proving resistant to all three existing classes of antifungal medicines.

The pathogens targeted most frequently by the eight companies are: CR-/ESBL producing Enterobacteriaceae (14 unique products) and P. aeruginosa (8 unique products). Within the Enterobacteriaceae family, the focus is on E. coli and Klebsiella pneumoniae.

WHO and CDC each categorise pathogens into multiple tiers to determine the level of risk from AMR. The highest risk categories are ‘critical’ and ‘urgent’ respectively

GSK leads in this area followed by Pfizer and Shionogi. These three companies have increased the number of their projects targeting critical and urgent priorities since the last iteration of the AMR Benchmark. 

Three companies are developing vaccines targeting pathogens categorised as critical and/or urgent: GSK (C. difficile and N. gonorrhoea), Johnson & Johnson (E. coli) and Pfizer (C.difficile). 

Of the eight companies assessed, GSK has the largest R&D pipeline targeting bacteria and fungi in scope. 19 out of 31 projects in their pipeline (61%) are in discovery/preclinical stage.

Few vaccine projects for gram-negative pathogens

Approximately one third of the pipeline comprises vaccine R&D projects. Vaccines are a critical tool for preventing the spread of infectious diseases, and
thereby the development and spread of AMR. Overall, S. pneumoniae followed by Enterobacteriaceae are targeted by most vaccine candidates in the pipeline.

However, very few vaccine candidates target other gram-negative pathogens in scope. This leaves some concerning gaps, such as for A. baumannii, an opportunistic pathogen that is associated with hospital outbreaks, as well as for P. aeruginosa. Both placed by WHO and CDC in the highest risk categories.

Six of the companies evaluated are developing vaccines (30) for the pathogens in scope. Shionogi is new to this group in 2021, having entered a collaboration with HanaVax to develop a vaccine against S. pneumoniae. GSK is developing 16 vaccines, more than any other company. 

It is followed by Pfizer, with four. Both have clinical-stage vaccine candidates targeting C. difficile. These are the only clinical-stage vaccine candidates, alongside GSK’s Bexsero (targeting N. gonorrhoeae) and Johnson & Johnson’s ExPEC9V vaccine (targeting E. coli), these C. difficile vaccines, targeting pathogens in the critical and/or urgent categories. 

Promising candidates

PFIZER
C. difficile vaccine (PF-06425090)
Phase III

This innovative vaccine in Phase III would represent the first available vaccine against C. difficile, a pathogen categorised as an urgent threat by the CDC. This pathogen causes diarrhoeal disease. Severe, life-threatening cases present mostly in older patients. 

Stewardship & Access plan: Assuming regulatory and clinical success, Pfizer would seek to register the product in countries with the highest local burden of disease and explore equitable pricing strategies. Given the lack of data in many countries, particularly LMICs, Pfizer is conducting real world data research studies in several LMICs to strengthen its understanding of burden and unmet need and better assess current burden of disease.

GSK
M. Tuberculosis prophylactic vaccine M72/AS01E (GSK692342)

Phase II

This innovative vaccine currently in Phase II trials shows up to 50% efficacy in the prevention of tuberculosis in adults, which is high compared to rates achieved by other candidates.

Access plan: In 2020, GSK licensed the vaccine to the Bill & Melinda Gates Medical Research Institute (Gates MRI). The Gates MRI now leads the candidate development and will sponsor future clinical trials, while GSK will provide the AS01 adjuvant. This agreement increases the likelihood that the candidate is optimised for use in low-income countries and that it is available shortly after approval in countries with a high burden of tuberculosis.

Medicine and vaccine projects target priority bacteria and fungi: The figure shows, per pathogen, how many products are in discovery/preclinical stages and which ones are in clinical development from the eight companies in scope. The pathogens receiving the most attention include Enterobacteriaceae, S. aureus, S. pneumonia and M. tuberculosis. Projects are included for each pathogen that they target, which means some projects are included more than once. Details about specific resistance profiles are in Appendix V.Adaptations of commercialised products are named with their brand name. Not all projects disclosed to the Benchmark are included in this table due to confidentiality agreements.

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved